/Idexx%20Laboratories%2C%20Inc_%20outside%20lab-by%20Sundry%20Photography%20via%20iStock.jpg)
IDEXX Laboratories, Inc. (IDXX), headquartered in Westbrook, Maine, operates in pet healthcare innovation with a market capitalization of $51.3 billion. The company delivers cutting-edge diagnostics and software for companion animals, livestock, poultry, dairy, and water testing, reaching customers in over 175 countries. Its key segments - Companion Animal Group; Water Quality Products; and Livestock, Poultry & Dairy – blend precision, technology, and global reach to advance animal and environmental health.
IDEXX Laboratories has been on a roll this year, with shares climbing 55.2% year-to-date (YTD), far outpacing the S&P 500 Index’s ($SPX) 9.9% return during the same period. Over the past 52 weeks, IDXX rose roughly 32.6%, again leaving the S&P 500’s 15.1% return behind.
Zoom in even within its sector, IDXX stock stands out - while the S&P Healthcare Equipment SPDR (XHE) has slipped 7.1% over 52 weeks and 7.2% YTD, IDXX continues to shine, proving resilience and market leadership.
IDXX’s robust outperformance stems largely from the company’s blowout Q2 2025 earnings release on Aug. 4. Its revenue rose 11% year over year (YoY) to $1.1 billion, and EPS came in at $3.63, up 49% from the prior-year quarter, both beating Wall Street’s projections.
This performance was driven by sustained momentum from the “puppy boom” tailwind, widespread adoption of the new inVue Dx analyzer, and stronger recurring diagnostic revenues alongside favorable foreign exchange effects. The company has also raised its full-year EPS outlook to $12.40 to $12.76 range.
For the current fiscal year, ending in December 2025, analysts project IDEXX’s EPS to be $12.61, up 18.2% YoY on a diluted basis. The company has consistently beaten expectations, surpassing consensus EPS estimates in each of its last four quarterly earnings reports.
The stock has a consensus “Moderate Buy” rating overall. Of the 12 analysts covering IDXX, six recommend a “Strong Buy,” one advises a “Moderate Buy,” and the remaining five are playing it safe with a “Hold” rating.
The current configuration has remained largely consistent over the past few months. But compared to two months ago, it reflects a slightly improved sentiment with “Strong Buy” ratings now inching up from five to six.
On Aug. 5, Jefferies lifted IDXX’s price target to $785 from $625 while maintaining a “Buy” rating, citing strong Q2 results and robust profitability.
The mean price target of $722.60 represents a premium of 12.6% to IDXX’s current price. Meanwhile, Jefferies’ Street-high price target of $785 suggests an upside potential of 22.3%.
On the date of publication, Sristi Jayaswal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
